- Home
- QFIN vs TGTX Comparison
QFIN vs TGTX Comparison
Compare QFIN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- TGTX
- Stock Information
- Founded
- QFIN 2016
- TGTX 1993
- Country
- QFIN China
- TGTX United States
- Employees
- QFIN N/A
- TGTX N/A
- Industry
- QFIN Finance: Consumer Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- TGTX Health Care
- Exchange
- QFIN Nasdaq
- TGTX Nasdaq
- Market Cap
- QFIN 5.9B
- TGTX 5.4B
- IPO Year
- QFIN 2018
- TGTX 1995
- Fundamental
- Price
- QFIN $38.49
- TGTX $32.91
- Analyst Decision
- QFIN Strong Buy
- TGTX Strong Buy
- Analyst Count
- QFIN 1
- TGTX 6
- Target Price
- QFIN $37.50
- TGTX $40.67
- AVG Volume (30 Days)
- QFIN 1.6M
- TGTX 2.3M
- Earning Date
- QFIN 11-19-2024
- TGTX 11-04-2024
- Dividend Yield
- QFIN 2.97%
- TGTX N/A
- EPS Growth
- QFIN 42.14
- TGTX N/A
- EPS
- QFIN 4.99
- TGTX N/A
- Revenue
- QFIN $2,449,056,522.00
- TGTX $264,790,000.00
- Revenue This Year
- QFIN $6.22
- TGTX $43.74
- Revenue Next Year
- QFIN $4.03
- TGTX $64.30
- P/E Ratio
- QFIN $7.68
- TGTX N/A
- Revenue Growth
- QFIN 9.41
- TGTX 39.53
- 52 Week Low
- QFIN $13.71
- TGTX $12.84
- 52 Week High
- QFIN $40.31
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- QFIN 65.01
- TGTX 55.20
- Support Level
- QFIN $37.55
- TGTX $30.41
- Resistance Level
- QFIN $40.31
- TGTX $35.03
- Average True Range (ATR)
- QFIN 1.34
- TGTX 1.55
- MACD
- QFIN 0.16
- TGTX -0.33
- Stochastic Oscillator
- QFIN 89.69
- TGTX 51.78
About QFIN Qifu Technology Inc.
Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.